The Hydration Purge: Why India’s ORS Market is Shrinking—and Why That’s Good for You

NEW DELHI – India’s oral rehydration solution (ORS) market, long a staple of the country’s medicine cabinets and summer survival kits, is undergoing a seismic shift. Recent data reveals a significant downturn in sales value, but the cause isn’t a lack of thirst—it’s a regulatory crackdown on what health officials call “misleading” marketing.

Following a landmark October 2025 directive from the Food Safety and Standards Authority of India (FSSAI), the hydration industry has been forced to strip the “ORS” label from hundreds of sugary beverages. The result? A market correction that saw sector value growth plunge by 26% year-on-year in March 2026. While the numbers look grim for manufacturers, public health experts are hailing the move as a critical victory for patient safety.

The End of the “Sugar Trap”

For years, the Indian market was flooded with “ORS-like” drinks. These products often featured bright packaging, fruit flavors, and the letters “ORS” prominently displayed. However, many were classified as “Food Business Operator” (FBO) products—essentially sugary soft drinks—rather than pharmaceutical-grade rehydration salts.

Under the FSSAI’s previous, more lenient guidelines, these brands could use the term “ORS” as long as they included a small disclaimer stating they did not follow the World Health Organization (WHO) formula. The October 2025 order ended this practice, prohibiting the use of “ORS” as a brand name, prefix, or suffix for any product not approved as a drug by the Central Drugs Standard Control Organisation (CDSCO).

“The confusion was lethal,” says Dr. Sivaranjani Santosh, a Hyderabad-based pediatrician whose legal advocacy helped spark the FSSAI’s intervention. “We were seeing children hospitalized with severe dehydration and electrolyte imbalances because parents, acting in good faith, were giving them what they thought was medicine, but was actually just flavored sugar water.”

Market Shock: By the Numbers

The financial fallout has been immediate. According to PharmaTrac data, the market is feeling the “regulatory chill” during what is usually its peak season:

• Monthly Decline: Sales value dropped to ₹85 crore in March 2026, down from ₹115 crore in March 2025.

• Leader Impact: Electral (FDC Ltd.), which historically controls over half the market, saw its Moving Annual Total (MAT) value decline by 7%.

• Overall Trend: The 12-month MAT for the category stood at ₹1,128 crore, an 8% drop—a sharp reversal from the 13% compound annual growth rate seen over the previous five years.

Sheetal Sapale, vice-president (commercial) at PharmaTrac, suggests the decline is a mix of regulatory enforcement and a “high base” effect from the previous year. However, industry insiders admit that removing non-compliant products has effectively “dismantled the marketing architecture” that many FMCG (Fast-Moving Consumer Goods) brands relied on.

The Science: Why the Formula Matters

To the average consumer, “water, salt, and sugar” might seem simple. But clinically, ORS is a precise bio-chemical tool. The WHO-recommended formula uses a specific ratio to trigger the “sodium-glucose cotransport” mechanism in the small intestine.

When a drink has too much sugar—as many of the now-banned “lifestyle” hydration drinks did—it can cause osmotic diarrhea. Essentially, the high sugar concentration in the gut pulls even more water out of the body’s tissues and into the intestine, worsening the very dehydration the drink was meant to fix.

Expert Perspective: Quality Over Quantity

While the sales dip might worry investors, medical professionals are relieved. “This isn’t about stifling business; it’s about clinical integrity,” explains an independent public health analyst. “India has made massive strides in reducing under-five mortality from diarrheal diseases. We cannot allow that progress to be undone by misleading labels.”

The medical community is now actively steering parents back toward CDSCO-approved sachets. These are regulated as drugs, ensuring that every gram of powder matches the life-saving WHO specifications.

However, the shift does present challenges. Some industry voices argue that the strict classification as a “drug” could make it harder for rural populations to access hydration products in local grocery shops that don’t hold pharmacy licenses. Furthermore, the cost of reformulation and seeking CDSCO approval may lead to price hikes for the consumer in the short term.

What This Means for Your Family

As India enters the peak heat of May, the advice for consumers is clear: Read the label, not the brand name.

1. Look for the Approval: Genuine ORS will now increasingly be found in pharmacies rather than the soda aisle. Look for “WHO Formulation” or CDSCO licensing information on the pack.

2. Avoid the “Fruit” Trap: If a product tastes like a sweet fruit juice, it is likely too high in sugar for clinical dehydration.

3. Emergency Home Mix: If a verified packet isn’t available, the WHO recommends a simple home-made version: six level teaspoons of sugar and half a level teaspoon of salt dissolved in one liter of clean water.

The Road Ahead

The “hydration purge” of 2026 marks a turning point in Indian consumer protection. As the market stabilizes, experts expect a new wave of innovation focused on low-osmolarity, pharmaceutical-grade products. For now, the decline in sales is a small price to pay for a public that is better informed and better protected against one of the country’s most common health threats.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

• Economic Times Health. (April 2026). ORS sales melt in March after govt’s stricter labelling norms. Source